Tianjin Hankang Pharmaceutical Biotechnology Co. Ltd.

Main purpose: This study used the phenarenic acid tablets (10 mg) certified by Tianjin Hanrui Pharmaceutical Co., Ltd. as the test preparation and the phenarenic acid tablets (trade name: Keshenda, specification: 10 mg) certified by Bayer AG as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To evaluate the pharmacokinetic characteristics of acetaminophen injection after single administration of 325 mg and 1000 mg, and after multiple administration of 500 mg in healthy Chinese subjects. Secondary objective: To investigate the safety of acetaminophen injection.

Using 5 mg tofacitinib citrate tablets produced by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd. as the test preparation and 5 mg tofacitinib citrate tablets (trade name: Shangjie®/Xeljanz®) produced by Pfizer Manufacturing Deutschland GmbH as the reference preparation, the pharmacokinetic behaviors of a single fasting/postprandial oral tofacitinib citrate tablets in healthy Chinese subjects were compared according to the relevant provisions of the bioequivalence test, and a bioequivalence evaluation was conducted to provide a basis for the registration application and clinical application of the drug.